Felix Agbo

472 total citations
14 papers, 356 citations indexed

About

Felix Agbo is a scholar working on Neurology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Felix Agbo has authored 14 papers receiving a total of 356 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Neurology, 3 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Felix Agbo's work include Parkinson's Disease Mechanisms and Treatments (5 papers), Neurological disorders and treatments (3 papers) and Cancer Genomics and Diagnostics (3 papers). Felix Agbo is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (5 papers), Neurological disorders and treatments (3 papers) and Cancer Genomics and Diagnostics (3 papers). Felix Agbo collaborates with scholars based in United States, Japan and Brazil. Felix Agbo's co-authors include Peter Barker, Adrian M. Senderowicz, Edward A. Sausville, Michael A. Carducci, Sonya Zabludoff, Richard Knight, Nilofer S. Azad, Patricia LoRusso, Lisa Malburg and Mary Flanagan Quinn and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and Journal of the American Academy of Child & Adolescent Psychiatry.

In The Last Decade

Felix Agbo

14 papers receiving 348 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Felix Agbo United States 8 232 192 45 38 37 14 356
L. Becks United States 6 223 1.0× 144 0.8× 46 1.0× 45 1.2× 26 0.7× 10 370
Eve Jary Australia 8 249 1.1× 91 0.5× 24 0.5× 30 0.8× 51 1.4× 8 372
Keara L. Redmond United Kingdom 9 310 1.3× 205 1.1× 49 1.1× 66 1.7× 16 0.4× 11 510
Kevin Conlon United States 11 315 1.4× 89 0.5× 26 0.6× 41 1.1× 29 0.8× 21 458
Charles Redwood United Kingdom 7 332 1.4× 84 0.4× 18 0.4× 24 0.6× 16 0.4× 10 456
Seong Whan Jeong South Korea 9 344 1.5× 128 0.7× 37 0.8× 29 0.8× 11 0.3× 12 439
Shaoyi Li China 9 296 1.3× 312 1.6× 48 1.1× 7 0.2× 12 0.3× 15 509
Angela M. Ohm United States 10 249 1.1× 79 0.4× 31 0.7× 22 0.6× 6 0.2× 15 328
Amy R. Dwyer Australia 12 145 0.6× 167 0.9× 70 1.6× 27 0.7× 6 0.2× 22 405
Katherine Amato United States 6 218 0.9× 100 0.5× 32 0.7× 96 2.5× 10 0.3× 8 360

Countries citing papers authored by Felix Agbo

Since Specialization
Citations

This map shows the geographic impact of Felix Agbo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Felix Agbo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Felix Agbo more than expected).

Fields of papers citing papers by Felix Agbo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Felix Agbo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Felix Agbo. The network helps show where Felix Agbo may publish in the future.

Co-authorship network of co-authors of Felix Agbo

This figure shows the co-authorship network connecting the top 25 collaborators of Felix Agbo. A scholar is included among the top collaborators of Felix Agbo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Felix Agbo. Felix Agbo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Stocchi, Fabrizio, Elizabeth Peckham, Maria Francesca De Pandis, et al.. (2022). A Randomized Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson's Disease. Clinical Pharmacology in Drug Development. 11(9). 1068–1077. 4 indexed citations
2.
3.
Agbo, Felix, Ryan L. Crass, Sunny Chapel, et al.. (2021). Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson’s disease. Clinical and Translational Science. 14(4). 1464–1475. 8 indexed citations
4.
5.
Agbo, Felix, et al.. (2020). Exposure-response efficacy model of apomorphine sublingual film for the on-demand treatment of “OFF” episodes in patients with Parkinson's disease. Parkinsonism & Related Disorders. 79. e85–e86. 2 indexed citations
6.
Agbo, Felix, Khanh Bui, & Diansong Zhou. (2017). Population pharmacokinetic analysis of lanicemine (AZD6765), an NMDA channel blocker, in healthy subjects and patients with major depressive disorder. Journal of Clinical Pharmacy and Therapeutics. 42(5). 539–546. 7 indexed citations
7.
Chapel, Sunny, et al.. (2017). 1.40 Lurasidone Exposure Response in Pediatric Bipolar Depression: Simulation and Comparison to Adults. Journal of the American Academy of Child & Adolescent Psychiatry. 56(10). S165–S165. 1 indexed citations
8.
Bui, Khanh, Diansong Zhou, Felix Agbo, & Jian Guo. (2015). Effect of multiple intravenous doses of lanicemine (AZD6765) on the pharmacokinetics of midazolam in healthy subjects. The Journal of Clinical Pharmacology. 55(9). 1024–1030. 7 indexed citations
9.
Sausville, Edward A., Patricia LoRusso, Michael A. Carducci, et al.. (2014). Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 73(3). 539–549. 144 indexed citations
10.
Seto, Takashi, Taito Esaki, Fumihiko Hirai, et al.. (2013). Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology. 72(3). 619–627. 78 indexed citations
11.
Seto, Takashi, Taito Esaki, Fumihiko Hirai, et al.. (2012). Phase I dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumors.. Journal of Clinical Oncology. 30(15_suppl). 3045–3045. 5 indexed citations
12.
Sausville, Edward A., P. LoRusso, Michael A. Carducci, et al.. (2011). Phase I dose-escalation study of AZD7762 in combination with gemcitabine (gem) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3058–3058. 12 indexed citations
13.
Ho, Alan L., J. C. Bendell, Gary K. Schwartz, et al.. (2011). Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3033–3033. 27 indexed citations
14.
Mauras, Nelly, et al.. (2009). Pharmacokinetics and Pharmacodynamics of Anastrozole in Pubertal Boys with Recent-Onset Gynecomastia. The Journal of Clinical Endocrinology & Metabolism. 94(8). 2975–2978. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L. Becks Breakdown of academic impact, for papers by Eve Jary Breakdown of academic impact, for papers by Keara L. Redmond Breakdown of academic impact, for papers by Kevin Conlon Breakdown of academic impact, for papers by Charles Redwood Breakdown of academic impact, for papers by Seong Whan Jeong Breakdown of academic impact, for papers by Shaoyi Li Breakdown of academic impact, for papers by Angela M. Ohm Breakdown of academic impact, for papers by Amy R. Dwyer Breakdown of academic impact, for papers by Katherine Amato
Rankless by CCL
2026